Business Wire

CA-NOMINAL

22.4.2024 19:29:30 CEST | Business Wire | Press release

Share
Nominal Emerges From Stealth With Backing From General Catalyst, Lux Capital, Founders Fund, for Navigating Mission-Critical Data Analytics

Nominal, a company specializing in creating end-to-end data analysis solutions for industrial engineering teams, emerged from stealth to provide a faster, more reliable way to review test data and validate mission-critical systems. The startup raised $7.5M in Seed funding led by Lux Capital with support from Founders Fund and $20M in their Series A led by General Catalyst. Additional investors include Haystack VC, XYZ Ventures, Human Capital, Box Group, and Overmatch.

Nominal specializes in creating software solutions for the Aerospace, Defense, Industrial Machinery, Transportation, and Energy sectors with various partnerships across the U.S. government. The company is led by co-founder and CEO Cameron McCord, who has extensive experience in the private sector at prominent startups Anduril, Applied Intuition, and Saildrone and as a venture capitalist, and in the public sector as a veteran Nuclear Submarine Officer and Congressional Liaison for the Navy. McCord works closely with his co-founders Bryce Strauss, a former Lockheed Martin Space division systems engineer who worked on inter-planetary robotic missions and building software tools for engineers, and Jason Hoch, an experienced software engineer who has diverse experience creating data products for startups, Fortune 500 companies, and governments.

Nominal's platform is designed to handle sensitive government and industrial data. The company's leadership team brings over 15 years of combined experience in both hardware and software from organizations like SpaceX, Palantir, Anduril, Applied Intuition, NASA, Microsoft, and more.

“Building trust in industrial systems and the data that these systems generate is core to our mission at Nominal. As aerospace, defense, and industrial systems have rapidly become more complex and software-defined, the software tools and infrastructure that engineers and operators use to make sense of and validate these systems have lagged in a costly and dangerous way.” Cameron McCord, Co-founder and CEO of Nominal said, “We’re choosing now to come out of stealth because we feel ready to accelerate our mission to help engineers that develop, test, and validate mission-critical industrial systems. We are on an industrial software collision course. Time is ticking - for our commercial customers, this means getting a product safely to market faster, and for our government customers, it means fielding reliable and tested systems for any mission.”

With Nominal, teams can quickly test and deploy their complex hardware systems. Nominal is dedicated to providing a robust, end-to-end solution that simplifies workflows, fosters collaboration, and seamlessly scales with the evolving needs of its valued customers and partners. Nominal also enables teams and organizational-level collaboration and visibility to reflect the multidisciplinary and iterative nature of engineering. The more people in an engineering organization who can view a comprehensive data story, the better the understanding and insights gained.

"When we first met Nominal, what stood out to us was the intentionality by which Cameron, Bryce, and Jason are building the company. Nominal’s modern software suite is purpose-built for hardware engineers to manage the complex workflows of testing and developing high-stakes, breakthrough hardware systems. By hitting the industrial software collision course head-on, we believe Nominal can help unlock a renaissance of industrial innovation,” said Paul Kwan, Managing Partner, General Catalyst.

Nominal is utilizing this latest infusion of capital to uphold its commitment to delivering innovative solutions to the defense and aerospace sectors, including the rollout of its full-stack data analysis solution designed to facilitate and expedite the process of analyzing and reviewing test data for engineering teams. Beyond new product initiatives to meet growing customer demands, the company also intends to grow its teams and enhance its security and deployment capabilities.

About Nominal

Nominal is igniting the next industrial revolution. By allowing for rapid and accurate review of test data and the validation of critical systems through its comprehensive data analysis platform, Nominal provides modern workflows specifically tailored to the needs of engineering teams that develop, validate, and monitor hardware. At Nominal, we believe hardware engineers deserve the world’s best software. We are fully committed to helping our users more efficiently and effectively test and deploy mission-critical systems that will change the world. Nominal currently supports mission-critical data analysis and testing at companies across the aerospace, defense, energy, and industrial spheres including Varda Space, Muon Space, REGENT, Radiant Nuclear, the U.S. Air Force, and others. We are supported by leading venture investors such as General Catalyst, Lux Capital, Founders Fund, Haystack, XYZ Ventures, Human Capital, BoxGroup, and Overmatch. To learn more about Nominal and its innovative solutions, please visit nominal.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418799842/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye